RANO 2D and 3D Measurements as a Companion Diagnostic Tool in NeuroQuant Brain Tumor

When it comes to brain tumor diagnosis and management, accurate measurement is crucial for guiding treatment decisions and monitoring patient progress. The Response Assessment in Neuro-Oncology (RANO) criteria, which rely on both 2D and 3D measurements, have become the standard for evaluating brain tumor size and response to treatment.

The Importance of Accurate Tumor Measurement

For patients with brain tumors, small differences in measurements can have a significant impact on treatment outcomes. Traditional 2D measurements, while effective, have limitations when it comes to capturing the full scope of tumor growth or reduction. This is where 3D measurements come in, offering a more comprehensive view of tumor size and shape.

How NeuroQuant Streamlines RANO Measurements

NeuroQuant’s Brain Tumor module simplifies the RANO measurement process by automatically segmenting and quantifying tumors in both 2D and 3D. By providing clinicians with consistent, accurate data, NeuroQuant reduces the time spent manually analyzing scans and enhances diagnostic precision. With the ability to model tumors in three dimensions, clinicians can better assess tumor volume and progression, improving treatment planning.

In conclusion, NeuroQuant’s integration of RANO 2D and 3D measurements provides a powerful companion diagnostic tool for clinicians. By automating this process, NeuroQuant ensures that healthcare providers can make more informed decisions, ultimately improving patient outcomes.

More Resources

04/22/2025

Cortechs.ai Receives Health Canada Approval to Expand Sales of AI-Powered Imaging Solutions in North America

Cortechs.ai receives Health Canada approval to expand its AI imaging solutions into Canada, advancing diagnostic precision and patient care.

04/02/2025

Pediatric Neuroimaging Insights: The NeuroQuant® Age Range Series

Brain volumetrics play a pivotal role in understanding pediatric neurological development. Explore how NeuroQuant® enhances neuroimaging from ages 3 to 100.

03/31/2025

How NeuroAlign CT Subtraction Maps Enhance Detection and Confidence in Neuroradiology

What if head CT assessment could be even faster and more accurate? Subtraction maps allow for improved detection and visualization of subtle interval changes.

03/27/2025

Cortechs.ai Joins Forces with Kryptonite Solutions as a Distribution Partner to Expand AI-Driven Neuroimaging Access in India

We are pleased to announce a strategic partnership with Kryptonite Solutions to distribute our innovative portfolio across India.

03/20/2025

Cortechs.ai Announces Strategic Distribution Partnership with Medical Horizons to Expand Presence in Italy, Turkey, and the Middle East

We are pleased to announce a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy.

03/18/2025

Unlocking the Power of AI Imaging in Multiple Sclerosis: How NeuroQuant® MS Enhances Lesion Detection and Monitoring

Unlock the power of AI-driven imaging with NeuroQuant® MS—enhancing lesion detection, monitoring, and personalized care for Multiple Sclerosis.
Scroll to Top